The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine

被引：9
|
作者：
Singh, Balwinder [1 ]
Bobo, William V. [2 ]
Rasmussen, Keith G. [1 ]
Stoppel, Cynthia J. [1 ]
Rico, Jose A., Jr. [1 ]
Schak, Kathryn M. [1 ]
Biernacka, Joanna M. [1 ,3 ]
Frye, Mark A. [1 ]
Vande Voort, Jennifer L. [1 ]
机构：
[1] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Depress Ctr, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Jacksonville, FL 32224 USA
[3] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
来源：
JOURNAL OF CLINICAL PSYCHIATRY | 2019年 / 80卷 / 06期
关键词：
D-ASPARTATE ANTAGONIST; TRIAL;
D O I：
10.4088/JCP.19l12852
中图分类号：
B849 [应用心理学];
学科分类号：
040203 ;
摘要：
引用
收藏
页数：6
相关论文
共 50 条
  • [1] INTRAVENOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION IN ADOLESCENTS?
    Cullen, Kathryn R.
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2016, 55 (10): : S284 - S284
  • [2] Remission of Treatment-Resistant Depression With Electroconvulsive Therapy and Ketamine
    Niemegeers, Peter
    Schrijvers, Didier
    Madani, Yamina
    Sabbe, Bernard G. C.
    JOURNAL OF ECT, 2014, 30 (03) : E31 - E32
  • [3] Habenula Connectivity and Intravenous Ketamine in Treatment-Resistant Depression
    Rivas-Grajales, Ana Maria
    Salas, Ramiro
    Robinson, Meghan E.
    Qi, Karen
    Murrough, James W.
    Mathew, Sanjay J.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2021, 24 (05): : 383 - 391
  • [4] The Bidirectional Relationship Between Body Mass Index and Treatment Outcome in Adolescents with Treatment-Resistant Depression
    Mansoor, Brandon
    Rengasamy, Manivel
    Hilton, Robert
    Porta, Giovanna
    He, Jiayan
    Spirito, Anthony
    Emslie, Graham J.
    Mayes, Taryn L.
    Clarke, Gregory
    Wagner, Karen Dineen
    Shamseddeen, Wael
    Birmaher, Boris
    Ryan, Neal
    Brent, David
    JOURNAL OF CHILD AND ADOLESCENT PSYCHOPHARMACOLOGY, 2013, 23 (07) : 458 - 467
  • [5] Intravenous ketamine therapy in a patient with a treatment-resistant major depression
    Liebrenz, Michael
    Borgeat, Alain
    Leisinger, Ria
    Stohler, Rudolf
    SWISS MEDICAL WEEKLY, 2007, 137 (15-16) : 234 - 236
  • [6] An Umbrella Review of Effectiveness of Intravenous Ketamine in Treatment-Resistant Depression
    Klassen, A. M.
    Baten, C.
    Shepherd, J. H.
    Zamora, G.
    Johnson-Venegas, E.
    Madugula, S. S.
    Woo, E.
    Miller, J. A.
    Sacchet, M. D.
    Hedges, D. W.
    Miller, C. H.
    EUROPEAN PSYCHIATRY, 2024, 67 : S86 - S87
  • [7] Continuation Phase Intravenous Ketamine in Adults With Treatment-Resistant Depression
    Bobo, William
    Voort, Jennifer Vande
    Morgan, Robert
    Rico, Jose
    Ritter, Matthew
    Tye, Susannah
    Frye, Mark
    NEUROPSYCHOPHARMACOLOGY, 2016, 41 : S168 - S169
  • [8] Lipidomic Signatures Informs Intravenous Racemic Ketamine Associated Remission in Treatment-Resistant Depression: A Pilot Study
    Singh, Balwinder
    MahmoudianDehkordi, Siamak
    Vande Voort, Jennifer
    Han, Xianlin
    Port, John
    Frye, Mark
    Daouk, Rima Kaddurah
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 (SUPPL 1) : 192 - 192
  • [9] Lipidomic Signatures Informs Intravenous Racemic Ketamine Associated Remission in Treatment-Resistant Depression: A Pilot Study
    Singh, Balwinder
    MahmoudianDehkordi, Siamak
    Voort, Jennifer Vande
    Han, Xianlin
    Port, John
    Frye, Mark
    Daouk, Rima Kaddurah
    NEUROPSYCHOPHARMACOLOGY, 2022, 47 : 192 - 192
  • [10] Lipidomic Signatures Inform Intravenous Racemic Ketamine Associated Remission in Treatment-Resistant Depression: A Feasibility Trial
    Singh, Balwinder
    MahmoudianDehkordi, Siamak
    Voort, Jennifer Vande
    Han, Xianlin
    Port, John
    Frye, Mark
    Kaddurah-Daouk, Rima
    BIOLOGICAL PSYCHIATRY, 2023, 93 (09) : S23 - S24
12345